NVO Novo Nordisk

   By Dominic Chopping 
 

Danish insulin maker Novo Nordisk A/S (NOVO-B.KO) has bought a manufacturing facility in West Lebanon, New Hampshire, U.S. from Olympus Biotech, it said Wednesday.

Novo Nordisk said it intends to use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals.

It added that some of the plant's former employees have been offered jobs, which will initially focus on planning of the future plant setup. Final plans will determine potential and timing for future staffing increases.

The companies have agreed not to disclose the terms of the acquisition.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires